326 related articles for article (PubMed ID: 25688892)
21. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
[TBL] [Abstract][Full Text] [Related]
22. Empagliflozin/metformin (Synjardy) for type 2 diabetes.
Med Lett Drugs Ther; 2015 Dec; 57(1484):172-4. PubMed ID: 26670554
[No Abstract] [Full Text] [Related]
23. Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter.
Toderika Y; Ferguson N
Cardiol Rev; 2014; 22(2):97-104. PubMed ID: 24500116
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
[TBL] [Abstract][Full Text] [Related]
27. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Matthaei S
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
[No Abstract] [Full Text] [Related]
28. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
[TBL] [Abstract][Full Text] [Related]
30. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Ghosh A; Gupta R; Misra A
J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
[No Abstract] [Full Text] [Related]
31. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Bloomgarden Z
J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
[No Abstract] [Full Text] [Related]
32. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
[TBL] [Abstract][Full Text] [Related]
33. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Skolnik N; Bonnes H; Yeh H; Katz A
Postgrad Med; 2016 May; 128(4):356-63. PubMed ID: 27043045
[TBL] [Abstract][Full Text] [Related]
34. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
[TBL] [Abstract][Full Text] [Related]
35. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
Diabetes Care; 2015 Jul; 38(7):1218-27. PubMed ID: 25852208
[TBL] [Abstract][Full Text] [Related]
36. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S65-9. PubMed ID: 24481635
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
38. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
39. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
40. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
